Effect of Acetazolamide and Furosemide on Obesity-induced Glomerular Hyperfiltration
Status:
Completed
Trial end date:
2014-05-01
Target enrollment:
Participant gender:
Summary
Background:
Obesity is associated with a high prevalence of chronic kidney disease.The glomerular
hyperfiltration associated with obesity may play a role in the pathogenesis of obesity
associated chronic kidney disease. Attenuation of hyperfiltration by pharmacological means
may slow down the development and progression of chronic renal failure. The investigators
have previously shown that acetazolamide, a proximally acting diuretic that activates
tubuloglomerular feedback(TGF) by increasing solute delivery to the Macula DENSA, abates
glomerular hyperfiltration. The present study was designed to test the hypothesis that this
decrease in hyperfiltration is specific to acetazolamide and not due to a non specific
diuretic effect. The aim of the present study is to compare the effects of furosemide and
acetazolamide on glomerular hemodynamics in subjects with severe obesity.
Methods:
A randomized double-blind crossover controlled design will be used. Fifteen obese subjects
and ten subjects with normal body weight will participate in the study. Obese subjects will
undergo measurement of glomerular filtration rate (GFR)(inulin clearance), renal plasma flow
(RPF) (p-aminohippuric acid clearance), filtration fraction, fractional excretion of lithium
(FE LI) and blood pressure, before and after intravenous administration of furosemide 2 mg.
and acetazolamide 5 mg/kg BW. Ten subjects with normal body weight will undergo measurement
of renal function without administration of diuretics.